{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T19:34:14Z","timestamp":1784230454300,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"crossref"}]},{"name":"FWO-Vlaanderen","award":["G.0287.07"],"award-info":[{"award-number":["G.0287.07"]}]},{"DOI":"10.13039\/501100013845","name":"Foundation against Cancer","doi-asserted-by":"crossref","award":["SCIE2006-34"],"award-info":[{"award-number":["SCIE2006-34"]}],"id":[{"id":"10.13039\/501100013845","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Federal Office for Scientific, Technical and Cultural Affairs, Belgium"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.ejmech.2013.03.024","type":"journal-article","created":{"date-parts":[[2013,3,21]],"date-time":"2013-03-21T04:32:07Z","timestamp":1363840327000},"page":"713-721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Identification of novel FLT3 kinase inhibitors"],"prefix":"10.1016","volume":"63","author":[{"given":"Daphnie","family":"Pauwels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Klaassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idoya","family":"Lahortiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amuri","family":"Kilonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram","family":"Sweron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romuald","family":"Corbau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Chaltin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Marchand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Cools","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2013.03.024_bib1","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/cncr.22233","article-title":"Acute myeloid leukemia: epidemiology and etiology","volume":"107","author":"Deschler","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2013.03.024_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1200\/JCO.2007.15.4245","article-title":"Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group","volume":"27","author":"Buchner","year":"2009","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2013.03.024_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/1947601911408076","article-title":"Genetic abnormalities and challenges in the treatment of acute myeloid leukemia","volume":"2","author":"Kumar","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.ejmech.2013.03.024_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hon.739","article-title":"When epigenetics kills: MLL fusion proteins in leukemia","volume":"23","author":"Slany","year":"2005","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2013.03.024_bib5","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrc1169","article-title":"The role of FLT3 in haematopoietic malignancies","volume":"3","author":"Stirewalt","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2013.03.024_bib6","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2013.03.024_bib7","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood.V97.11.3589","article-title":"FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia","volume":"97","author":"Stirewalt","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2013.03.024_bib8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood.V97.1.89","article-title":"Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia","volume":"97","author":"Meshinchi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2013.03.024_bib9","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2013.03.024_bib10","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia","volume":"358","author":"Schlenk","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2013.03.024_bib11","first-page":"238","article-title":"Human FLT3\/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells","volume":"10","author":"Rosnet","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2013.03.024_bib12","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/eji.1830260715","article-title":"Flt3 ligand supports the differentiation of early B cell progenitors in the presence of interleukin-11 and interleukin-7","volume":"26","author":"Ray","year":"1996","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ejmech.2013.03.024_bib13","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1182\/blood.V87.4.1317.bloodjournal8741317","article-title":"The FLT3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow progenitor cells in\u00a0vitro","volume":"87","author":"Rusten","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2013.03.024_bib14","first-page":"1911","article-title":"Internal tandem duplication of the flt3 gene found in acute myeloid leukemia","volume":"10","author":"Nakao","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2013.03.024_bib15","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/sj.leu.2401130","article-title":"Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product","volume":"12","author":"Kiyoi","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2013.03.024_bib16","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","article-title":"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies","volume":"97","author":"Yamamoto","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2013.03.024_bib17","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/sj.onc.1203354","article-title":"Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines","volume":"19","author":"Hayakawa","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2013.03.024_bib18","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood-2006-02-003475","article-title":"Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia","volume":"108","author":"Kornblau","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2013.03.024_bib19","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","article-title":"Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3","volume":"28","author":"Fischer","year":"2010","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2013.03.024_bib20","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1182\/blood-2006-04-015560","article-title":"A\u00a0phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy","volume":"108","author":"Knapper","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2013.03.024_bib21","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","article-title":"AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)","volume":"114","author":"Zarrinkar","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2013.03.024_bib22","doi-asserted-by":"crossref","unstructured":"J. Cortes, A. Perl, C. Smith, T. Kovacsovics, H. Dombret, H. D\u00f6hner, A phase II open-label, AC220 monotherapy efficacy (ACE) study in patients with Acute Myeloid Leukemia (AML) with FLT3-ITD activating mutations: interim results, 16th Congress of the European Hematology Association, 2011.","DOI":"10.1182\/blood.V118.21.2576.2576"},{"key":"10.1016\/j.ejmech.2013.03.024_bib23","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.1182\/blood-2010-04-261867","article-title":"FLT3 as a therapeutic target in AML: still challenging after all these years","volume":"116","author":"Kindler","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2013.03.024_bib24","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/onc.2010.273","article-title":"Drug resistance in mutant FLT3-positive AML","volume":"29","author":"Weisberg","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2013.03.024_bib25","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nature11016","article-title":"Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia","volume":"485","author":"Smith","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2013.03.024_bib26","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood-2005-06-2469","article-title":"Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain","volume":"107","author":"Heidel","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2013.03.024_bib27","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1535-6108(03)00108-9","article-title":"PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease","volume":"3","author":"Cools","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2013.03.024_bib28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/sj.leu.2404064","article-title":"Chronic myeloproliferative disorders: a tyrosine kinase tale","volume":"20","author":"De Keersmaecker","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2013.03.024_bib29","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A\u00a0tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2013.03.024_bib30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0092-8674(94)90322-0","article-title":"Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation","volume":"77","author":"Golub","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2013.03.024_bib31","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2013.03.024_bib32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3324\/haematol.10692","article-title":"The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors","volume":"92","author":"Lierman","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2013.03.024_bib33","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/sj.leu.2400812","article-title":"Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines","volume":"11","author":"Yokota","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2013.03.024_bib34","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1182\/blood-2003-07-2479","article-title":"The EOL-1 cell line as an in\u00a0vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia","volume":"103","author":"Cools","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2013.03.024_bib35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF01702925","article-title":"Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens","volume":"62","author":"Hiddemann","year":"1991","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ejmech.2013.03.024_bib36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/CCO.0b013e328011a25f","article-title":"Ba\/F3 cells and their use in kinase drug discovery","volume":"19","author":"Warmuth","year":"2007","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.ejmech.2013.03.024_bib37","series-title":"Pharmaceutical Pyrazole Compositions Useful as Inhibitors of Protein Kinases","author":"Giese","year":"1996"},{"key":"10.1016\/j.ejmech.2013.03.024_bib38","series-title":"Small Molecule Compounds for Stem Cell Differentiation","author":"Mercola","year":"2010"},{"key":"10.1016\/j.ejmech.2013.03.024_bib39","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1535-6108(02)00070-3","article-title":"CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)","volume":"1","author":"Kelly","year":"2002","journal-title":"Cancer Cell"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523413001724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523413001724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T04:27:49Z","timestamp":1595564869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523413001724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":39,"alternative-id":["S0223523413001724"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2013.03.024","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of novel FLT3 kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2013.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}